Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Rituximab (MabThera®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1048. 2015 Authors' conclusions Rituximab (MabThera®) solution for subcutaneous injection is recommended as an option for use within NHS Wales for the treatment of adults for non-Hodgkin's lymphoma (NHL): for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy; and for the treatment of patients with CD20-positive diffuse large B cell NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal, Murine-Derived /therapeutic use; Female; Glucocorticoids /therapeutic uses; Immunosuppressive Agents /therapeutic use; Male; Nephrotic Syndrome /drug therapy Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32015000584 Date abstract record published 01/06/2015 |